Key Takeaways Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for ...

Taco Bell is re-upping its value menu game with the introduction of $5, $7 and $9 luxe cravings boxes, while TikTok is ...

Medicare has announced the expansion of coverage for Eli Lilly’s Zepbound, a breakthrough drug in the treatment of autoimmune ...

There is a photo that exemplifies the paradox of Robert F. Kennedy Jr.’s nomination as secretary of the Health and Human ...

Medicare’s block on obesity medication ... loss therapies like Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide), which generally have to be paid for out-of-pocket ...

El Lilly’s blockbuster weight-loss drug Zepbound is now eligible for coverage under Medicare prescription drug plans, when ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

Eli Lilly (LLY) is in advanced talks to buy cancer-focused biotech Scorpion Therapeutics in a deal worth up to $2.5B, people close to the talks ...

Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss ...

A health alert was issued for certain frozen Walmart empanadas that were mislabeled, which could pose a risk for some people ...

US intelligence finds no proof tying 'Havana syndrome' health issues to foreign actors, but 2 agencies say it's possible.

Lilly now plans to file for approval to add the heart failure indication to the label for tirzepatide, which is already sold as Mounjaro for type 2 diabetes and Zepbound for obesity, later this year.